About Celularity Inc.
https://www.celularity.comCelularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.
CEO
Robert Joseph Hariri
Compensation Summary
(Year 2023)
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
WALLEYE CAPITAL LLC
Shares:835.19K
Value:$13.53K
LINDEN ADVISORS LP
Shares:550.12K
Value:$8.91K
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND
Shares:350K
Value:$5.67K
Summary
Showing Top 3 of 19
About Celularity Inc.
https://www.celularity.comCelularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $5.28M ▼ | $16.17M ▼ | $-23.07M ▲ | -436.66% ▼ | $-0.88 ▲ | $-19.73M ▲ |
| Q2-2025 | $5.74M ▼ | $16.36M ▼ | $-24.52M ▼ | -427.55% ▼ | $-1.02 ▼ | $-20.75M ▼ |
| Q1-2025 | $11.43M ▼ | $18.36M ▼ | $-19.75M ▼ | -172.89% ▼ | $-0.84 ▼ | $-15.48M ▼ |
| Q4-2024 | $18.13M ▲ | $20.07M ▲ | $-13.29M ▲ | -73.31% ▲ | $-0.59 ▲ | $-7.6M ▲ |
| Q3-2024 | $9.3M | $16.94M | $-16.1M | -173.17% | $-0.73 | $-12.45M |
What's going well?
Gross profit and margins improved sharply this quarter, showing better control over product costs. Operating losses narrowed a bit, and other income helped soften the blow.
What's concerning?
Revenue is falling, expenses are much higher than sales, and the company is still losing a lot of money. Shareholders are being diluted, and the business relies on non-core income to offset losses.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $120K ▼ | $114.24M ▼ | $134.33M ▼ | $-20.09M ▲ |
| Q2-2025 | $863K ▲ | $120.28M ▼ | $145.78M ▲ | $-25.5M ▼ |
| Q1-2025 | $293K ▼ | $128.88M ▼ | $134.38M ▲ | $-5.51M ▼ |
| Q4-2024 | $738K ▲ | $132.68M ▲ | $123.84M ▲ | $8.84M ▼ |
| Q3-2024 | $133K | $128.84M | $111.56M | $17.28M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-23.08M ▲ | $-4.16M ▼ | $0 | $3.48M ▲ | $-743K ▼ | $-4.16M ▼ |
| Q2-2025 | $-24.52M ▼ | $-999K ▲ | $0 | $1.63M ▼ | $570K ▲ | $-999K ▲ |
| Q1-2025 | $-19.75M ▼ | $-2.99M ▼ | $0 ▲ | $2.32M ▲ | $-673K ▼ | $-2.99M ▼ |
| Q4-2024 | $-13.29M ▲ | $1.59M ▲ | $-1.56M ▼ | $643K ▲ | $681K ▲ | $1.54M ▲ |
| Q3-2024 | $-16.1M | $-144K | $-35K | $-79K | $-258K | $-179K |
Revenue by Products
| Product | Q4-2024 | Q3-2024 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 License Royalty and Other | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Product | $10.00M ▲ | $0 ▼ | $10.00M ▲ | $0 ▼ |
 Service | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Robert Joseph Hariri
Compensation Summary
(Year 2023)
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
WALLEYE CAPITAL LLC
Shares:835.19K
Value:$13.53K
LINDEN ADVISORS LP
Shares:550.12K
Value:$8.91K
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND
Shares:350K
Value:$5.67K
Summary
Showing Top 3 of 19